[1]
Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010; 15(1): 4-16.
[http://dx.doi.org/10.3109/13625180903427675] [PMID: 20136566]
[http://dx.doi.org/10.3109/13625180903427675] [PMID: 20136566]
[2]
Bishop J. Undertaking an oral contraceptive pill review. Nurs Stand 2017; 32(5): 52-63.
[http://dx.doi.org/10.7748/ns.2017.e10966] [PMID: 29094544]
[http://dx.doi.org/10.7748/ns.2017.e10966] [PMID: 29094544]
[3]
Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf 2014; 5(5): 201-13.
[http://dx.doi.org/10.1177/2042098614548857] [PMID: 25360241]
[http://dx.doi.org/10.1177/2042098614548857] [PMID: 25360241]
[4]
Cooper D, Patel P, Mahdy H. Oral Contraceptive Pills. 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430882/
[5]
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK304327/
[6]
Stocco B, Fumagalli HF, Franceschini SA, et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: An observational preliminary study. Medicine 2015; 94(4): e385.
[http://dx.doi.org/10.1097/MD.0000000000000385] [PMID: 25634167]
[http://dx.doi.org/10.1097/MD.0000000000000385] [PMID: 25634167]
[7]
Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016; 94(6): 678-700.
[http://dx.doi.org/10.1016/j.contraception.2016.04.014] [PMID: 27153743]
[http://dx.doi.org/10.1016/j.contraception.2016.04.014] [PMID: 27153743]
[8]
Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 2011; 9(2): 120-38.
[http://dx.doi.org/10.2450/2010.0066-10] [PMID: 21084000]
[http://dx.doi.org/10.2450/2010.0066-10] [PMID: 21084000]
[9]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II Type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules 2022; 27(7): 2048.
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[10]
Fajloun Z, Kovacic H, Annweiler C, Wu Y, Cao Z, Sabatier JM. SARS-CoV-2-induced neurological disorders in symptomatic COVID-19 and long COVID patients: Key role of brain renin-angiotensin system. Infect Disord Drug Targets 2022; 22(5): e060422203203.
[http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]
[http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]
[11]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in SARS-CoV-2-induced COVID-19. Molecules 2021; 26(22): 6945.
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[12]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27(9): 2903.
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[13]
Sabatier J-M, Fajloun Z, Abi Khattar Z, Kovacic H, Legros C. Why can high-level athletes develop very severe or fatal forms after intense exercise following SARS-CoV-2 infection or anti-COVID vaccination? Infect Disord Drug Targets 2023; 23. Epub ahead of print
[http://dx.doi.org/10.2174/1871526523666230111104355] [PMID: 36631923]
[http://dx.doi.org/10.2174/1871526523666230111104355] [PMID: 36631923]
[14]
Sabatier J-M, Fajloun Z, Legros C. COVID-19 and ehlers-danlos syndrome: The dangers of the Spike protein of SARS-CoV-2. Infect Disord Drug Targets 2023; 23(3): 26-8.
[http://dx.doi.org/10.2174/1871526523666230104145108] [PMID: 36600622]
[http://dx.doi.org/10.2174/1871526523666230104145108] [PMID: 36600622]
[15]
Deep vein thrombosis (DVT): Overview 2006. InformedHealth.org, InformedHealth.org [Internet]. Cologne, Germany: Mar 23, 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425364/
[16]
Olvera Lopez E, Ballard BD, Jan A. Cardiovascular disease. In: StatPearls: Florida 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535419/
[17]
Annweiler C, Cao Z, Papon N, Kovacic H, Sabatier JM. Counter-regulatory renin-angiotensin system: an important line of research to understand and limit the severity of COVID-19. Infect Disord Drug Targets 2022; 22(2): e100921196331.
[http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]
[http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]
[18]
Harb J, Debs N, Rima M, et al. SARS-CoV-2, COVID-19, and reproduction: effects on fertility, pregnancy, and neonatal life. Biomedicines 2022; 10(8): 1775.
[http://dx.doi.org/10.3390/biomedicines10081775] [PMID: 35892675]
[http://dx.doi.org/10.3390/biomedicines10081775] [PMID: 35892675]
[19]
Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Infect Disord Drug Targets 2020; 20(4): 407-8.
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]